Dirlotapide — Veterinary Vademecum Drug Reference

Dosage & Administration Guidelines

Species	Route	Dose	Frequency	Duration & Clinical Notes
Dog	PO	Initial dose: 0.05 mg/kg once daily; increase by 0.05 mg/kg at 2-week intervals up to a maximum of 0.2 mg/kg once daily	Once daily	Duration: Continue until target weight is achieved; typically 3-6 months Notes: Administer with food. Adjust dose based on body weight and response. Do not exceed 0.2 mg/kg/day.

Clinical Indications & Species Uses

General Indications

Weight loss in dogs

Dog (Canine)

Management of obesity in dogs
Weight loss and weight management in overweight or obese dogs

Pharmacology & Mechanism of Action

Drug Class: Microsomal triglyceride transfer protein (MTP) inhibitor | Pharmacological Group: Anti-obesity agent

Mechanism of Action: Dirlotapide is a selective inhibitor of microsomal triglyceride transfer protein (MTP) in the enterocytes of the small intestine. By inhibiting MTP, it blocks the assembly and secretion of chylomicrons, thereby reducing the absorption of dietary fats. This leads to a reduction in caloric intake and promotes weight loss. The drug acts locally in the gut with minimal systemic absorption.

Pharmacodynamics: Dirlotapide reduces intestinal fat absorption, leading to decreased body weight and body condition score in dogs. It also reduces serum triglyceride and cholesterol levels. The drug has a high specificity for intestinal MTP and does not significantly affect hepatic MTP, thus minimizing hepatotoxicity.

⚡ Pharmacokinetics Summary

Absorption: Dirlotapide is minimally absorbed after oral administration. The systemic bioavailability is low (approximately 1-2%) due to extensive first-pass metabolism and its local action in the gastrointestinal tract.

Distribution: The drug is primarily confined to the gastrointestinal tract. The small amount that is absorbed is highly protein-bound and distributed to tissues, but systemic exposure is minimal.

Metabolism: Dirlotapide is extensively metabolized in the liver and intestinal wall, primarily by ester hydrolysis and oxidation. The metabolites are excreted in the feces.

Excretion: The drug and its metabolites are eliminated mainly in the feces via biliary excretion. A small fraction may be excreted in the urine.

Half-Life: The half-life in dogs is approximately 1-2 hours for the parent drug, but the pharmacological effect is prolonged due to local action in the gut.

Bioavailability: Low oral bioavailability (<2%) due to poor absorption and extensive first-pass metabolism.

Protein Binding: Approximately 99% protein-bound in plasma (for the absorbed fraction).

Available Formulations & Strengths

Oral solution 5 mg/mL (PO)

Contraindications & Clinical Warnings

Contraindications:

Hypersensitivity to dirlotapide or any component of the formulation
Pregnancy or lactation (safety not established)
Use in cats or other species
Pre-existing liver disease or hepatic dysfunction
Concurrent use with other anti-obesity drugs

Warnings & Clinical Precautions:

Use with caution in dogs with a history of gastrointestinal disease
Monitor liver enzymes during therapy
Not for use in breeding, pregnant, or lactating dogs
Do not use in dogs with obesity due to endocrine disorders (e.g., hypothyroidism) unless the underlying condition is treated
Ensure adequate water intake
May cause reduced appetite; monitor food intake
Use only in dogs; safety in other species not established

Adverse Effects & Reactions

Common:

Vomiting
Diarrhea
Loose stools
Decreased appetite
Lethargy

Serious / Severe:

Hepatotoxicity (elevated liver enzymes)
Severe dehydration
Pancreatitis (rare)

Rare:

Allergic reactions
Ileus
Intestinal obstruction

Key Drug Interactions

Interacting Drug / Class	Clinical Effect & Mechanism	Severity
Corticosteroids	May counteract the weight loss effect of dirlotapide	Moderate
Other anti-obesity drugs	Additive effects or increased risk of adverse effects	High
Cyclosporine	Potential for increased cyclosporine levels due to altered lipid metabolism	Moderate

Overdose & Toxicity Management

Signs of Toxicity:

Severe vomiting
Diarrhea
Dehydration
Lethargy
Hepatic enzyme elevation

Emergency Treatment Protocol: There is no specific antidote. Treatment is symptomatic and supportive. Induce emesis if recent ingestion and the animal is conscious. Administer activated charcoal to reduce absorption. Provide fluid therapy for dehydration and electrolyte imbalances. Monitor liver function and provide supportive care.

Food Animal Withdrawal Times

Not approved for use in food-producing animals. Withdrawal times not established.

Storage, Handling & Regulatory Information

Storage Temperature: Store at controlled room temperature 20°C to 25°C (68°F to 77°F), excursions permitted between 15°C and 30°C (59°F and 86°F)

Handling & Special Conditions: Keep bottle tightly closed. Protect from freezing.

Dispensing Status: Prescription Required (Rx Only)

Approval Status: Approved by FDA for use in dogs (Slentrol®) for weight management.

Extra-Label (Off-Label) Use: Extra-label use in dogs is not permitted due to the drug's specific indication and safety profile. Use in other species is prohibited. In the US, extra-label use in food animals is prohibited.

Clinical Pearls & Practice Notes

💡 Clinical Insights: Dirlotapide is a unique anti-obesity agent for dogs that works by reducing intestinal fat absorption. It should be used as part of a comprehensive weight management program including diet and exercise. The dose should be titrated gradually to minimize gastrointestinal side effects. Regular monitoring of body weight, body condition score, and liver enzymes is recommended. The drug is not intended for long-term maintenance; once the target weight is achieved, the drug should be discontinued and a maintenance diet and exercise plan should be continued. Due to its mechanism, it is not effective in cats or other species.

References & Literature

📚 Plumb's Veterinary Drug Handbook
📚 Papich Veterinary Pharmacology and Therapeutics
📚 Compendium of Veterinary Products (CVP)